<div id="readability-page-1"><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>Penumbra ( (PEN) ) just unveiled an announcement. On May 6, 2026, Penumbra stockholders held a special meeting at which a quorum of 28,665,933 shares was present out of 39,324,084 shares outstanding and entitled to vote. Shareholders voted on three proposals related to the company’s planned acquisition by Boston Scientific, including a merger agreement, advisory executive compensation tied to the deal, and a potential adjournment of the meeting. Investors overwhelmingly approved the merger agreement with Boston Scientific, clearing a key condition for Penumbra to become a wholly owned subsidiary of the larger medical device company. Stockholders also backed, on an advisory basis, the compensation arrangements for Penumbra’s named executive officers in connection with the merger, while the adjournment proposal proved unnecessary since the merger vote passed, leaving only regulatory and other closing conditions as remaining hurdles before the transaction can be completed. The most recent analyst rating on (PEN) stock is a Hold with a $350.00 price target. To see the full list of analyst forecasts on Penumbra stock, see the PEN Stock Forecast page. Spark’s Take on PEN Stock According to Spark, TipRanks’ AI Analyst, PEN is a Neutral. The score is driven primarily by strong financial performance (growth, margin expansion, improving cash flow, and low leverage). Offsetting factors are a soft technical setup and an expensive valuation (high P/E with no dividend support), while the announced acquisition and strong preliminary results provide a constructive near-term catalyst subject to approval/closing risk. To see Spark’s full report on PEN stock, click here. More about Penumbra Penumbra, Inc., a U.S. medical technology company, develops and sells innovative neurovascular and vascular devices used to treat conditions such as stroke and peripheral vascular disease. Its products are primarily marketed to hospitals and specialized clinics, positioning the company as a key player in the interventional medical devices industry with a focus on minimally invasive therapies. Average Trading Volume: 595,957 Technical Sentiment Signal: Buy Current Market Cap: $12.75B </div>

SBIO

Penumbra shareholders approved the merger with Boston Scientific during a special meeting on May 6, 2026. A quorum of 28,665,933 shares voted on three proposals, including the merger agreement, which received overwhelming support. The advisory compensation for executives was also approved, while the adjournment proposal was deemed unnecessary. The merger will make Penumbra a wholly owned subsidiary of Boston Scientific, pending regulatory approvals. Analysts currently rate Penumbra stock as a Hold with a price target of $350.00, citing strong financial performance but noting concerns over valuation and technical setup.

Penumbra Shareholders Approve Merger with Boston Scientific